Grant: Project Grant
McGill University
$355,725.00
The effects, costs, and cost-effectiveness of Montreal's harm reduction interventions for people who inject drugs
EF 2019-20
Résumé
Background: Montreal, Quebec has one of the largest populations of PWID in the country (n~4000), and despite offering a variety of harm reduction interventions (e.g. supervised injection facilities (SIFs), needle and syringe programs (NSPs), and opioid agonist treatment (OAT)) continues to grapple with the ramifications of injection drug use including HIV and HCV transmission, and drug-related overdoses and deaths.
Objective: To conduct an extensive analyses of the effects, costs, and cost-effectiveness of SIFs, NSPs and OAT, in Montreal, Quebec.
Methods: We will use patient-level data from administrative health data sets capturing inpatient, out-patient and publicly covered pharmaceutical dispensations; local cohort and surveillance data; and published literature to simulate the effects of SIFs, NSPS, and OAT on the population of PWID (18 years and older) living in Montreal. The data will be used to evaluate the effects of these interventions on skin, soft tissue and vascular infections
(SSTVIs), HIV, hepatitis C, overdose, anoxic/toxicity-related brain injury, and death; estimate the health related costs of these medical events; and determine the cost-effectiveness of variations of the interventions. The results of these analyses will add much-needed insight into the burden of common and debilitating SSTVIs and anoxic/toxicity-related brain injury on the health of PWID, and the cost effectiveness of these harm reduction interventions in a city with a scattered population of PWID, whose primary drug is not opioid based, and where uptake of these interventions is not complete (e.g. SIFs not used at capacity).
Programme
Project Grant
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
418683
Name
Panagiotoglou Dimitra
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Population and Public Health
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Public, Community & Population Health 2
Projecttitle
The effects, costs, and cost-effectiveness of Montreal's harm reduction interventions for people who inject drugs
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$355,725
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Epidemiology; Health Economic Evaluation; Health Services Research; Population Health
Abstract
Background: Montreal, Quebec has one of the largest populations of PWID in the country (n~4000), and despite offering a variety of harm reduction interventions (e.g. supervised injection facilities (SIFs), needle and syringe programs (NSPs), and opioid agonist treatment (OAT)) continues to grapple with the ramifications of injection drug use including HIV and HCV transmission, and drug-related overdoses and deaths.
Objective: To conduct an extensive analyses of the effects, costs, and cost-effectiveness of SIFs, NSPs and OAT, in Montreal, Quebec.
Methods: We will use patient-level data from administrative health data sets capturing inpatient, out-patient and publicly covered pharmaceutical dispensations; local cohort and surveillance data; and published literature to simulate the effects of SIFs, NSPS, and OAT on the population of PWID (18 years and older) living in Montreal. The data will be used to evaluate the effects of these interventions on skin, soft tissue and vascular infections
(SSTVIs), HIV, hepatitis C, overdose, anoxic/toxicity-related brain injury, and death; estimate the health related costs of these medical events; and determine the cost-effectiveness of variations of the interventions. The results of these analyses will add much-needed insight into the burden of common and debilitating SSTVIs and anoxic/toxicity-related brain injury on the health of PWID, and the cost effectiveness of these harm reduction interventions in a city with a scattered population of PWID, whose primary drug is not opioid based, and where uptake of these interventions is not complete (e.g. SIFs not used at capacity).
Competitiondate
202003
Approvedterm2
4 yrs 0 mth
Pinamesdelim
Panagiotoglou, Dimitra
Approvedterm
4 ans 0 mois
Cihrcontribution2
~ $355,725~ $0~